Related Experiment Video
Updated: Jan 16, 2026

Innovative Strategies for Organ Preservation in Heart Transplantation: Uniform Cooling Preservation and Ex-situ Normothermic Perfusion
Published on: November 28, 2025
Plasma Exchange in the Setting of Immune-Mediated Multiple Organ Failure in the Cardiac ICU During ECMO: A Case
Sonia Labarinas1, Kalpana Norbisrath1, Ibeh Nnaemeka2
1Children's Heart Institute, Pediatric Cardiac Critical Care, Advanced Cardiopulmonary Therapies and Transplantation, University of Texas-Health Science Center at Houston, Houston, Texas, USA.
Insights
Therapeutic plasma exchange (TPE) may improve platelet counts in critically ill children with thrombocytopenia-associated multiple organ failure (TAMOF) on extracorporeal membrane oxygenation (ECMO). This study found TPE reduced organ severity scores but noted a high mortality rate.
Area of Science:
- Pediatric Critical Care Medicine
- Cardiovascular Surgery
- Hematology
Background:
- Extracorporeal membrane oxygenation (ECMO) is a life-support measure for pediatric cardio-respiratory failure.
- Thrombocytopenia-associated multiple organ failure (TAMOF) is a severe complication in children on ECMO.
- Therapeutic plasma exchange (TPE) is a potential treatment for TAMOF.
Purpose of the Study:
- To describe the use and outcomes of TPE in critically ill children with TAMOF undergoing ECMO.
- To evaluate the impact of TPE on platelet counts and organ severity scores in this patient population.
Main Methods:
- A single-center retrospective case series of seven pediatric patients with congenital cardiac disease on ECMO and diagnosed with TAMOF.
- Patients received TPE using a centrifugation-based apheresis instrument with bivalirudin for anticoagulation.
- Data collected included patient demographics, ECMO characteristics, TPE details, platelet counts, and organ severity scores.
Main Results:
- Seven patients underwent 30 TPE sessions; median sessions per patient was 3.
- Median platelet count increased significantly post-TPE (45 to 64 × 10^9/L, p < 0.001) without transfusions.
- Modified organ severity index decreased significantly (13 to 12, p < 0.001).
- The overall mortality rate was 71%.
Conclusions:
- Therapeutic plasma exchange may be effective in improving platelet counts in pediatric TAMOF patients on ECMO.
- TPE demonstrated a reduction in organ severity scores in this cohort.
- Despite potential benefits, the high mortality rate highlights the severity of TAMOF in ECMO patients.
Abstract:
Extracorporeal membrane oxygenation (ECMO) is a last resort treatment for children with cardio-respiratory failure. Some of these patients will develop thrombocytopenia-associated multiple organ failure (TAMOF), which is sometimes managed with therapeutic plasma exchange (TPE). Our objective is to describe critically ill children on ECMO who underwent TPE for TAMOF. We conducted a single-center retrospective case series of seven children with congenital cardiac disease, requiring ECMO, diagnosed with TAMOF, and treated with TPE between 12/2023 and 6/2024. A centrifugation-based apheresis instrument was used to process 1.5 total blood volume. One packed red blood cell was used to prime the apheresis circuit. Systemic bivalirudin was used for anticoagulation. Seven patients (median age: 55 days, median weight: 4.0 kg, median bypass time: 172 min, 100% VA ECMO, 85% central cannulation, 100% bivalirudin) underwent a total of 30 TPE sessions. The median number of sessions per patient was 3, with a median time to first session of 27.3 h after cannulation. Plasma was used as the replacement fluid in all sessions, with a median volume of 168 mL/kg. The median platelet count increased from 45 × 109/L (38; 54) pre-TPE to 64 (IQR: 45; 75, p < 0.001) post-TPE, despite no platelet transfusions during TPE. The modified organ severity index decreased significantly from 13 to 12 (p < 0.001). The mortality rate was 71%. TPE may improve platelet counts and reduce organ severity scores in critically ill children with TAMOF on ECMO.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy

